Does the increase of exosomal microRNAs reflect an activated immune system in melanoma?
Poster Dec 12, 2013
Nina Koliha, Florian S. Dreyer , Jochen Dindorf , Andreas Bosio, Andreas S. Baur , and Stefan Wild
One of the new classes of potential cancer biomarkers are microRNAs. MicroRNAs are non-coding RNAs that suppress the translation of their target mRNAs by binding to the 3’ untranslated region³. On the one hand, melanoma-derived exosomes are discussed as vesicles for degradation of anti-tumor microRNAs. On the other hand, exosomal microRNAs might be active in recipient cells4, e.g., by repressing anti-tumorigenic immune responses. To investigate these possibilities, we profiled the microRNA content of exosomes from melanoma cell lines and plasma of melanoma patients. Informed consent was collected according to guidelines for medical and research ethics.
Is Oxford Nanopore Technology Ready for Clinical Diagnostics?Poster
Our objective is to validate diagnostic services using Oxford Nanopore’s Minion in the first instance and to evaluate the cost and performance compared to existing sequencing technology in areas such as tumour DNA sequencing (and circulating tumour DNA), virology, microbiology, genetics and HLA-typing.READ MORE
Combining a Real-Time In Vitro Cell Viability Assay and RNA Extraction from the Same 3D SpheroidsPoster
We report here the results of using a novel small molecule probe that viable cells convert into a substrate for a shrimp-derived luciferase to generate a signal proportional to the number of viable cells.READ MORE
Performance of the D5000 and High Sensitivity D5000 ScreenTape Assays for the 4200 TapeStation SystemPoster
Here, we focus on quantification, sizing, and sensitivity of both D5000 ScreenTape assays.READ MORE